Adenocarcinoma of prostate
Item
histologically or cytologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Hormone refractory prostate cancer
Item
castration-resistant disease defined as:
boolean
C1328504 (UMLS CUI [1])
Serum testosterone measurement
Item
serum testosterone level: ≤ 50 ng/dl (1.7 nmol/l)
boolean
C0428413 (UMLS CUI [1])
Male Castration | Maintenance Androgen suppression | Luteinizing Hormone-releasing Hormone Agonist | Luteinizing hormone releasing hormone antagonist product | polyestradiol phosphate
Item
bilateral orchiectomy or maintenance on androgen ablation therapy with luteinizing-hormone-releasing hormone (lhrh) agonist or antagonist, or polyestradiol phosphate
boolean
C0007347 (UMLS CUI [1])
C0024501 (UMLS CUI [2,1])
C1515985 (UMLS CUI [2,2])
C1518041 (UMLS CUI [3])
C1276926 (UMLS CUI [4])
C0071554 (UMLS CUI [5])
Raised prostate specific antigen Quantity | Prostate specific antigen measurement
Item
serum psa (prostate specific antigen) progression defined as 2 subsequent increases in psa over a previous reference value (a minimum of 2 ng/ml [μg/l]) or
boolean
C0178415 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
Disease Progression Bone Radiography | Raised prostate specific antigen | Raised prostate specific antigen Absent
Item
radiographic evidence of disease progression in bone (according to prostate cancer clinical trials working group 2 [pcwg2] criteria) with or without psa progression
boolean
C0242656 (UMLS CUI [1,1])
C0262950 (UMLS CUI [1,2])
C0034571 (UMLS CUI [1,3])
C0178415 (UMLS CUI [2])
C0178415 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
ECOG performance status | Relationship Prostate cancer metastatic to bone
Item
eastern cooperative oncology group performance status (ecog ps) 0 to 2. in case of ecog ps 2, the ps has to be due to metastatic prostate cancer to the bone.
boolean
C1520224 (UMLS CUI [1])
C0439849 (UMLS CUI [2,1])
C4076671 (UMLS CUI [2,2])
Neoplasm Metastasis Skeletal Quantity | Hot spot Quantity Bone scintigraphy
Item
two or more skeletal metastases (≥ 2 hot spots) on bone scintigraphy within 8 weeks of randomization
boolean
C0027627 (UMLS CUI [1,1])
C0521324 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3829661 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C3889015 (UMLS CUI [2,3])
Neoplasm Metastasis Visceral
Item
history of visceral metastasis, or visceral metastases
boolean
C0027627 (UMLS CUI [1,1])
C0442045 (UMLS CUI [1,2])
Lymphadenopathy | Lymph nodes Diameter Short axis
Item
lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter
boolean
C0497156 (UMLS CUI [1])
C0024204 (UMLS CUI [2,1])
C1301886 (UMLS CUI [2,2])
C0522488 (UMLS CUI [2,3])
CNS metastases
Item
central nervous system (cns) metastases
boolean
C0686377 (UMLS CUI [1])
Cytotoxic Chemotherapy Prostate carcinoma | Cytotoxic Chemotherapy Planned Prostate carcinoma
Item
treatment with cytotoxic chemotherapy for prostate cancer within the previous 4 weeks prior to randomization, or planned treatment with cytotoxic chemotherapy agents for prostate cancer during the treatment period or follow-up
boolean
C0677881 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0677881 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C0600139 (UMLS CUI [2,3])
Chronic condition Associated with Abnormal bone growth | Osteitis Deformans
Item
chronic conditions associated with non-malignant abnormal bone growth (e.g. confirmed paget's disease of bone)
boolean
C4315615 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0005941 (UMLS CUI [1,3])
C0029401 (UMLS CUI [2])
Radium-223 dichloride
Item
prior treatment with radium-223 dichloride
boolean
C3541342 (UMLS CUI [1])
Therapeutic radiology procedure Systemic | Teleradiotherapy procedure Hemibody
Item
prior systemic radiotherapy and hemibody external radiotherapy
boolean
C1522449 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0419095 (UMLS CUI [2,1])
C3846139 (UMLS CUI [2,2])